A5072721892- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Atmospheric Ozone and Climate
- Spectroscopy and Laser Applications
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Atmospheric and Environmental Gas Dynamics
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Fungal Infections and Studies
- Hemoglobinopathies and Related Disorders
- Electron and X-Ray Spectroscopy Techniques
- Cancer Treatment and Pharmacology
- Antifungal resistance and susceptibility
- Lung Cancer Research Studies
Hospices Civils de Lyon
2016-2025
Hôpital Lyon Sud
2016-2025
Université Claude Bernard Lyon 1
2006-2024
Hôpital l'Archet
2024
Groupe de Spectrométrie Moléculaire et Atmosphérique
2009-2021
Centre de Recherche en Cancérologie de Lyon
2010-2021
Assistance Publique – Hôpitaux de Paris
2005-2021
Université Paris Cité
2010-2021
Centre National de la Recherche Scientifique
2009-2021
Université de Reims Champagne-Ardenne
2009-2021
Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials showed efficacy manageable toxic effects.In this multi-institutional phase 3 trial, we randomly assigned adults heavily pretreated ALL, 2:1 ratio, receive either blinatumomab standard-of-care...
This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients newly diagnosed acute myeloid leukemia (AML) poor- or intermediate-risk cytogenetics.Patients (N = 485) age ≥ 65 years were randomly assigned 1:1 to receive 20 mg/m(2) per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks TC (supportive care cytarabine subcutaneous injection 10 weeks). The primary end point was...
We analyzed the benefits of a risk-adapted postremission strategy in adult lymphoblastic leukemia (ALL), and re-evaluated stem-cell transplantation (SCT) for high-risk ALL.A total 922 patients entered onto trial according to risk groups: standard-risk ALL (group 1), 2), Philadelphia chromosome-positive 3), CNS-positive 4). All received standard four-drug/4-week induction course. Patients from group 1 who achieved complete remission (CR) after one course therapy were randomly assigned between...
Retrospective comparisons have suggested that adolescents or teenagers with acute lymphoblastic leukemia (ALL) benefit from pediatric rather than adult chemotherapy regimens. Thus, the aim of present phase II study was to test a pediatric-inspired treatment, including intensified doses nonmyelotoxic drugs, such as prednisone, vincristine, L-asparaginase, in patients ALL up age 60 years.Between 2003 and 2005, 225 (median age, 31 years; range, 15 years) Philadelphia chromosome-negative were...
Treatment with rituximab has improved the outcome for patients non-Hodgkin's lymphoma. Patients B-lineage acute lymphoblastic leukemia (ALL) may also have CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding to chemotherapy could improve in such patients, this hypothesis not been tested a randomized trial.We randomly assigned adults (18 59 years of age) CD20-positive, Philadelphia chromosome (Ph)-negative ALL receive or without rituximab, event-free...
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (AML). Here we report an independent review EFS, final overall (OS), additional safety results from ALFA-0701. Patients (n=271) aged 50-70 years AML were randomized receive conventional induction (3+7daunorubicin+cytarabine) with/without 3 mg/m2 on...
Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed question whether NPM1m MRD may be used as a predictive factor allogeneic stem cell transplantation (ASCT) benefit. Patients Methods Among 229 who were treated Acute Leukemia French Association 0702 (ALFA-0702) trial, evaluation was available 152 first remission. nonfavorable AML...
Purpose The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 (N/F) mutations compared with unmutated T-ALL. Despite this, one third of patients N/F-mutated T-ALL experienced relapse. Patients and Methods In series 212 adult T-ALLs included the multicenter randomized GRAALL-2003 -2005 trials, we searched additional N/K-RAS PTEN defects (mutations gene...
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or prior AML-directed therapies. Patients were first preselected a CCR (azacitidine, intermediate-dose cytarabine, low-dose supportive care) and then randomized (1:1) enasidenib 100 mg per day CCR. The primary...
Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor-naive patients with mIDH1R132 relapsed/refractory (R/R) acute myeloid leukemia (AML) received olutasidenib monotherapy 150 mg twice daily in the pivotal cohort this study. The median age participants was 71 years (range, 32-87 years) and number prior regimens by 2 (1-7). rate complete remission (CR) plus CR partial hematologic recovery (CRh)...
Recent advances have included insights into the clinical value of genomic abnormalities in acute myeloid leukemia (AML) and consequently development numerous targeted therapeutic agents that improved outcome. In this setting, various trials recently explored novel either used alone or combination with intensive chemotherapy low-intensity treatments. Among them, menin inhibitors could represent a group therapies AML driven by rearrangement lysine methyltransferase 2A (KMT2A) gene, previously...